Infliximab (Inflectra®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000593
English
Authors' recommendations: Infliximab (Inflectra®) is recommended as an option for restricted use within NHS Wales. Infliximab (Inflectra® should be prescribed within its licensed indications in accordance with NICE or AWMSG guidance for infliximab (Remicade®), the reference product. Infliximab (Inflectra®)should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Details
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Anti-Inflammatory Agents
  • Antirheumatic Agents
Contact
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.